KINDERHOOK, N.Y.--(BUSINESS WIRE)--American Bio Medica Corporation (OTCPK:ABMC) announced today that they have completed the research and development of a new rapid urine drug test that will detect compounds found in synthetic marijuana; commonly known as “K2”or “Spice”. The new test will detect JWH-018 and JWH-073, two of the most common compounds found in synthetic marijuana products. The test will also indicate positive or negative results for 16 additional cross-reacting compounds at certain cut-off levels. JWH-073 can be detected as low as 25 ng/ml, the lowest detection level available on the market today.
ABMC’s Chief Executive Officer Melissa A. Waterhouse stated, “This test for K2 will compliment our existing product lines; it is fast, easy to use, cost effective and it will provide our customers with the level of quality they are used to getting with ABMC products. We have no doubt it will be the most effective rapid K2 detection tool on the market.”
The K2 test will be marketed in the United States for forensic use only. The Company is accepting pre-orders, and the test will be available for shipment to ABMC customers in early 2016.
For more information on ABMC or its drug testing products, please visit www.abmc.com.
About American Bio Medica Corporation
American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to “penny stock” rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled “Risk Factors” in the Company's annual report on Form 10-K for the year ended December 31, 2014, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.